Trial Profile
A 24 Month, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Corticosteroids; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus; Tacrolimus
- Indications Liver transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms RAD
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Nov 2021 Results of pooled analysis from two global pivotal clinical trials (H2304 [NCT00622869] and H2307 [NCT01888432] presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 13 Nov 2018 Results of a pooled analysis from H2304 and H2307 studies, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases